Public filings / ARWR on Yahoo Finance (opens in a new tab)
ARWR: insider buying, 13F holders, analyst moves
Arrowhead Pharmaceuticals, Inc.
A summary of public filings about Arrowhead Pharmaceuticals, Inc. For the latest insider history, price chart, analyst changes and activist filings, open the live lookup.
SEC Form 13F · Q2 2026
4 of our 100 managers hold ARWR
Combined reported value $1.20B; 2 sold out since Q1 2026.
Holders among our 100 managers: 2 in Q3 2023, 4 in Q2 2026.
| Manager | Value | % of portfolio | Change vs Q1 2026 |
|---|---|---|---|
| Avoro Capital Advisors | $925.6M | 8.31% | Added |
| Baker Bros. Advisors | $162.4M | 0.81% | Unchanged |
| Deerfield Company | $113.2M | 1.18% | Trimmed |
| Polen Capital | $539K | 0.01% | New |
Important information
Facts from public SEC filings, shown for information only. Not a recommendation. Not individualized investment advice. Gulfstream Capital and its clients may hold positions in securities shown.